Search - tctmd.com

Displaying 721 - 740 of 970

Sort: Relevancy | Date

Presentation TCT 2014

Two-Year Clinical Results of Patients Randomized to 3- or 12-Month Dual Antiplatelet After Endeavor Zotarolimus Eluting Stent Implantation In OPTIMIZE

Presenter: Fausto Feres

September 16, 2014

Presentation TCT 2014

Short-Duration Versus Guideline-Recommended 12-Month Dual Antiplatelet Therapy After Drug-Eluting Stents Implantation

Presenter: Giulio Stefanini

September 16, 2014

Presentation TCT 2014

Impact of platelet reactivity on clopidogrel after PCI with 2nd generation DES on late lumen loss_

Presenter: Naoei Isomura

September 16, 2014

Presentation TCT 2014

Comparable outcomes on single use of clopidogrel vs_ dual antiplatelet therapy after coronary stenting in patients with acute myocardial infarction

Presenter: Jun-Hyok Oh

September 16, 2014

Presentation TCT 2014

Antiplatelet Effects of Clopidogrel and Aspirin During 6 Months of Follow-up After Stent Implantation: An ADAPT-DES Substudy

Presenter: Dietmar Trenk

September 16, 2014

Presentation TCT 2014

TCT 475: Triple Antithrombotic Therapy Versus Dual Antiplatelet Therapy in Patients with Atrial Fibrillation Undergoing Drug-Eluting Stent Implantation

Presenter: E. Magnus Ohman, Freek W.A. Verheugt, C. Michael Gibson, Dong Oh Kang

September 15, 2014

Presentation TCT 2014

TCT 474: Triple vs Dual Antithrombotic Therapy in Patients with Atrial Fibrillation and Acute Coronary Syndromes: The AVIATOR Registry

Presenter: E. Magnus Ohman, Freek W.A. Verheugt, C. Michael Gibson, Georgios Christodoulidis

September 15, 2014

Presentation TCT 2014

When Should Aspirin Be Dropped From Triple Therapy? Musings on Woest and Beyond

Presenter: E. Magnus Ohman, Freek W.A. Verheugt, C. Michael Gibson, Harvey D. White

September 15, 2014

Presentation TCT 2014

Definitely To Prevent Stent Thrombosis and MI!

Presenter: Gregg W. Stone

September 15, 2014

Presentation TCT 2014

Definitely Not An Expensive Way to Increase Bleeding Without Much Benefit!

Presenter: Nick Curzen

September 15, 2014

Presentation TCT 2014

Controversies in Aortic Valve Disease: Challenging Clinical Scenarios (Asymptomatic AS, Low-Flow Low-Gradient AS, and Concomitant CAD)

Presenter: Blase A. Carabello, George D. Dangas

September 15, 2014

Presentation TCT 2014

TCT 460: Bivalirudin Versus Heparin During Percutaneous Coronary Intervention: A Meta-analysis of Randomized Trials

Presenter: John A. Bittl, Tullio Palmerini, Salvatore Cassese, MD

September 15, 2014

Presentation TCT 2014

TRANSLATE-ACS: A Large-Scale Registry Comparing Patterns of Use and One-Year Outcomes with Prasugrel Versus Clopidogrel in Patients with Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention

Presenter: Stefan K. James, Cindy L. Grines, Tracy Y. Wang

September 15, 2014

Presentation TCT 2014

SECURITY: A Prospective, Randomized Trial of Six Months Versus 12 Months of Dual Antiplatelet Therapy Following Coronary Drug-Eluting Stent Implantation

Presenter: Roxana Mehran, Harvey D. White, Antonio Colombo

September 15, 2014

Presentation TCT 2014

ISAR-TRIPLE: A Prospective, Randomized Trial of Six Weeks Versus Six Months of Clopidogrel in Patients Treated with Concomitant Aspirin and Oral Anticoagulant Therapy Following Coronary Drug-Eluting Stent Implantation

Presenter: Roxana Mehran, Harvey D. White, Nikolaus Sarafoff

September 15, 2014

Presentation TCT 2014

BRIGHT: A Prospective, Randomized Trial of Bivalirudin Monotherapy Versus Heparin Monotherapy Versus Heparin Plus Tirofiban in Patients with Acute Myocardial Infarction Undergoing Coronary Intervention

Presenter: Roxana Mehran, Harvey D. White, Yaling Han

September 15, 2014

News Conference News TCT 2014

SYMPLICITY HTN-3 Substudy Examines BP Response Factors in African Americans

Yael L. Maxwell

September 15, 2014

News Conference News TCT 2014

OPTIMIZE: Short-term DAPT Safe 2 Years After ZES Implantation

September 15, 2014

News Conference News TCT 2014

Keynote Address Focuses on Newer DES, Problematic Subgroups

September 15, 2014

Presentation TCT 2014

Does Cilostazol Have a Role as an Antiplatelet Agent in the Contemporary DES Era (and in Triple Therapy Decisions)?

Presenter: Robert A. Harrington, Ajay J. Kirtane, Thomas D. Stuckey, Frederick Feit

September 14, 2014

Advertisement

Two-Year Clinical Results of Patients Randomized to 3- or 12-Month Dual Antiplatelet After Endeavor Zotarolimus Eluting Stent Implantation In OPTIMIZE

Short-Duration Versus Guideline-Recommended 12-Month Dual Antiplatelet Therapy After Drug-Eluting Stents Implantation

Impact of platelet reactivity on clopidogrel after PCI with 2nd generation DES on late lumen loss_

Comparable outcomes on single use of clopidogrel vs_ dual antiplatelet therapy after coronary stenting in patients with acute myocardial infarction

Antiplatelet Effects of Clopidogrel and Aspirin During 6 Months of Follow-up After Stent Implantation: An ADAPT-DES Substudy

TCT 475: Triple Antithrombotic Therapy Versus Dual Antiplatelet Therapy in Patients with Atrial Fibrillation Undergoing Drug-Eluting Stent Implantation

TCT 474: Triple vs Dual Antithrombotic Therapy in Patients with Atrial Fibrillation and Acute Coronary Syndromes: The AVIATOR Registry

When Should Aspirin Be Dropped From Triple Therapy? Musings on Woest and Beyond

Definitely To Prevent Stent Thrombosis and MI!

Definitely Not An Expensive Way to Increase Bleeding Without Much Benefit!

Controversies in Aortic Valve Disease: Challenging Clinical Scenarios (Asymptomatic AS, Low-Flow Low-Gradient AS, and Concomitant CAD)

TCT 460: Bivalirudin Versus Heparin During Percutaneous Coronary Intervention: A Meta-analysis of Randomized Trials

TRANSLATE-ACS: A Large-Scale Registry Comparing Patterns of Use and One-Year Outcomes with Prasugrel Versus Clopidogrel in Patients with Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention

SECURITY: A Prospective, Randomized Trial of Six Months Versus 12 Months of Dual Antiplatelet Therapy Following Coronary Drug-Eluting Stent Implantation

ISAR-TRIPLE: A Prospective, Randomized Trial of Six Weeks Versus Six Months of Clopidogrel in Patients Treated with Concomitant Aspirin and Oral Anticoagulant Therapy Following Coronary Drug-Eluting Stent Implantation

BRIGHT: A Prospective, Randomized Trial of Bivalirudin Monotherapy Versus Heparin Monotherapy Versus Heparin Plus Tirofiban in Patients with Acute Myocardial Infarction Undergoing Coronary Intervention

SYMPLICITY HTN-3 Substudy Examines BP Response Factors in African Americans

OPTIMIZE: Short-term DAPT Safe 2 Years After ZES Implantation

Keynote Address Focuses on Newer DES, Problematic Subgroups

Does Cilostazol Have a Role as an Antiplatelet Agent in the Contemporary DES Era (and in Triple Therapy Decisions)?

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content